122 related articles for article (PubMed ID: 38579085)
21. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
22. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
23. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
Zheng P; Li N; Zhan X
Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
[TBL] [Abstract][Full Text] [Related]
25. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
[TBL] [Abstract][Full Text] [Related]
26. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
[TBL] [Abstract][Full Text] [Related]
27. The role of the HIF-1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer.
Wang JZ; Zhu W; Han J; Yang X; Zhou R; Lu HC; Yu H; Yuan WB; Li PC; Tao J; Lu Q; Wei JF; Yang H
Cancer Commun (Lond); 2021 Jul; 41(7):560-575. PubMed ID: 33991457
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
30. Identification of M5c regulator-medicated methylation modification patterns for prognosis and immune microenvironment in glioma.
Xiao Z; Li J; Liang C; Liu Y; Zhang Y; Zhang Y; Liu Q; Yan X
Aging (Albany NY); 2023 Nov; 15(21):12275-12295. PubMed ID: 37934565
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
Front Immunol; 2023; 14():955949. PubMed ID: 37006317
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
Chen L; Lin J; Wen Y; Chen Y; Chen CB
Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
[TBL] [Abstract][Full Text] [Related]
33. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
34. 5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer.
Li Z; Wang S; Chen Y; Huang Y; Li T
Dis Markers; 2022; 2022():3117359. PubMed ID: 35371346
[TBL] [Abstract][Full Text] [Related]
35. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer.
Wu T; Li S; Yu C; Wu Y; Long H
Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838
[TBL] [Abstract][Full Text] [Related]
36. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
38. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value and underlying mechanism of autophagy-related genes in bladder cancer.
Peng S; Ma S; Yang F; Xu C; Li H; Lu S; Zhang J; Jiao J; Han D; Shi C; Zhang R; Yang AG; Zhang K; Wen W; Qin W
Sci Rep; 2022 Feb; 12(1):2219. PubMed ID: 35140317
[TBL] [Abstract][Full Text] [Related]
40. Identification of immune-related genes as prognostic factors in bladder cancer.
Zhu J; Wang H; Ma T; He Y; Shen M; Song W; Wang JJ; Shi JP; Wu MY; Liu C; Wang WJ; Huang YQ
Sci Rep; 2020 Nov; 10(1):19695. PubMed ID: 33184436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]